Kust Davor, Kruljac Ivan, Peternac Ana Šverko, Ostojić Jelena, Prpić Marin, Čaržavec Dubravka, Gaćina Petar
a Department of Oncology and Nuclear medicine, University Hospital Center "Sestre milosrdnice" , University of Zagreb Medical School , Croatia.
b Department of Endocrinology, Diabetes and Metabolic Diseases "Mladen Sekso", University Hospital Center "Sestre Milosrdnice" , University of Zagreb Medical School , Croatia.
Acta Clin Belg. 2016 Jun;71(3):175-7. doi: 10.1179/2295333715Y.0000000065. Epub 2016 Feb 7.
To best of our knowledge, this is the first reported case of pericardial and pleural effusions combined with ascites, precipitated with severe sunitinib-induced hypothyroidism. A 58-year-old man presented in our emergency department due to dyspnoea and dry cough. Sixteen months earlier, the patient underwent left nephrectomy due to metastatic renal cell adenocarcinoma (RCC), and therapy with sunitinib was initiated postoperatively. Thyroid function was not assessed during the therapy. On admission, all laboratory findings were within normal range. Computed tomography of the chest detected voluminous bilateral pleural effusions and mild pericardial effusion, and echocardiography revealed pericardial effusion. Thoracocentesis was carried out three times, and cytological examination showed no signs of malignant cells. After assessment of the thyroid function, neglected hypothyroidism was registered. Substitution therapy with levothyroxine was initiated, and thyroid function normalised 2 weeks later. Few days after the last thoracocentesis, his condition suddenly got worse. Thoracocentesis was repeated, and microbiological analysis of the exudate came positive for Klebsiella pneumoniae and Streptococcus pneumoniae. Despite the implemented therapeutic measures, his clinical condition progressively deteriorated. The patient died 27 days after the admission, hospital-acquired pneumonia was identified as the cause of death. Our case emphasises the necessity of careful monitoring and management of side-effects in patients who receive sunitinib. Hypothyroidism is a known cause of pleural, pericardial and abdominal effusions, as reported in several case reports. Timely initiation of substitution levothyroxine therapy can decrease unnecessary pauses in the therapy with sunitinib, as well as prevent development of severe symptoms.
据我们所知,这是首例报告的心包和胸腔积液合并腹水的病例,由严重的舒尼替尼诱导的甲状腺功能减退引发。一名58岁男性因呼吸困难和干咳就诊于我们的急诊科。16个月前,该患者因转移性肾细胞腺癌接受了左肾切除术,并于术后开始使用舒尼替尼治疗。治疗期间未评估甲状腺功能。入院时,所有实验室检查结果均在正常范围内。胸部计算机断层扫描检测到大量双侧胸腔积液和轻度心包积液,超声心动图显示有心包积液。进行了三次胸腔穿刺术,细胞学检查未发现恶性细胞迹象。评估甲状腺功能后,发现存在被忽视的甲状腺功能减退。开始使用左甲状腺素替代治疗,2周后甲状腺功能恢复正常。最后一次胸腔穿刺术后几天,他的病情突然恶化。再次进行胸腔穿刺术,渗出液的微生物分析显示肺炎克雷伯菌和肺炎链球菌呈阳性。尽管采取了治疗措施,他的临床状况仍逐渐恶化。患者入院27天后死亡,医院获得性肺炎被确定为死因。我们的病例强调了对接受舒尼替尼治疗的患者进行仔细的副作用监测和管理的必要性。如几份病例报告中所报道,甲状腺功能减退是胸腔、心包和腹腔积液的已知原因。及时开始左甲状腺素替代治疗可以减少舒尼替尼治疗中不必要的中断,并预防严重症状的发展。